| 2022 MEDICAL ONCOLOGY MEASURES | VRB MEASURE |
|---|---|
| Chemotherapy intent (curative vs. non-curative) documented before or within 2 weeks after administration | |
| Oral chemotherapy monitored and addressed on visit/contact following start of therapy | |
| Tobacco cessation counseling administered or patient referred in past year | |
| NK1RA & olanzapine prescribed or administered with high-risk chemotherapy | X |
| NK1RA or olanzapine administered with 1st cycle low/moderate emetic risk (lower is better) | X |
| Complete family history documented in patients with invasive cancer | |
| GCSF administered to patients who received chemotherapy with non-curative intent (lower is better) | |
| Hospice enrollment | X |
| Hospice enrollment & enrollment within 7 days of death (lower is better) | X |
| Hospice enrollment for greater than 30 days | |
| Chemotherapy administered within the last 2 weeks of life (lower is better) |